IMV Announced Update and Planned 2023 Milestones to Advance Clinical Development of its Lead Therapeutic, MVP-S; IMV Expects Its Current Cash Position Will Be Sufficient To Fund Operations Into The Second Half of 2023

Author: Charles Gross | January 08, 2023 08:38pm
IMV Inc. (NASDAQ:IMV, TSX:IMV) today outlined its planned 2023 milestones to advance the clinical development of its lead therapeutic, maveropepimut-S (MVP-S). Presenting details on initial response data from the ongoing VITALIZE DLBCL trial at the Immuno-Oncology 360° conference on February 10, 2023 Expects preliminary clinical response data from the AVALON Phase 2b trial in H2 2023 Recently strengthened financial position with the completion of a $9M financing Appoints Shabnam Kazmi to its Board of Directors following the retirement of Julia P. Gregory Based on its current operating plans, IMV expects its current cash position will be sufficient to fund operations into the second half of 2023.

Posted In: IMV TSX:IMV